Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target Unchanged
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics with an unchanged $13 price target. The decision is driven by regulatory clarity from FDA alignment on the Phase 3 design for CAD-1005, which de-risks the development path. Analysts highlight potential commercialization opportunities by 2030, though securing funding or partnerships remains a key obstacle to initiating Phase 3 trials.
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics, Inc. today and set a price target of $13.00.
Joseph Pantginis has given his Buy rating due to a combination of factors tied to both regulatory progress and long‑term value potential. He views the recent FDA alignment on the primary endpoint and placebo‑controlled Phase 3 design for CAD-1005 in heparin-induced thrombocytopenia as a key de-risking event that clarifies the registrational path and supports a more predictable development timeline.
Pantginis also highlights that the planned interim analysis and the company’s projected path toward an NDA filing in 2029 and a potential 2030 launch underpin a meaningful commercialization opportunity, which he believes is not fully reflected in the current share price. While he acknowledges that securing adequate funding and/or a partnership remains the main obstacle to initiating Phase 3, he expects the improved regulatory clarity to enhance Cadrenal’s attractiveness to partners, justifying a continued Buy rating and an unchanged $13 price target.